SCHEMBL890933

SCHEMBL890933

SCCOc1ccc(OCCS)c(OCCS)c1OCCS

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.36
CHRM2 P08172 2/20 0.36
CHRM1 P11229 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ACHE P22303 1/20 0.36
KCNH2 Q12809 1/20 0.36
HIF1A Q16665 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL890767 0.85 LMNA (0.52) LMNACHRM2CHRM1ALOX15TSHR
SCHEMBL890869 0.76 KDM4E (0.54) LMNASMN1; SMN2HDAC3HDAC4HDAC1
SCHEMBL891041 0.75 INPPL1 (0.41) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL891039 0.73 MAPK1 (0.35) SMN1; SMN2HDAC3HDAC4HDAC1HDAC7
SCHEMBL6903419 0.72
SCHEMBL890813 0.72 INPPL1 (0.43) LMNAHDAC3HDAC4HDAC1HDAC7
SCHEMBL891033 0.69 HDAC3 (0.52) SMN1; SMN2HDAC3HDAC4HDAC1HDAC7
SCHEMBL21250347 0.69 KDM4E (0.41) LMNASMN1; SMN2HDAC3HDAC4HDAC1
SCHEMBL9228272 0.68 FOLH1 (0.38) SMN1; SMN2MAPTNPSR1MEN1NPC1
SCHEMBL12002671 0.66 CA12 (0.61) LMNAMAPTALDH1A1NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062512-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT KUREHA CORPORATION (JP) 2026-03-05 US disclosed
US-20260062548-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION KUREHA CORPORATION (JP) 2026-03-05 US disclosed
EP-4582459-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION Kureha Corporation (JP) 2025-07-09 EP disclosed
EP-4582463-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT Kureha Corporation (JP) 2025-07-09 EP disclosed
EP-3483219-B1 TRANSPARENT PLASTIC SUBSTRATE AND PLASTIC LENS HOYA LENS THAILAND LTD (TH) 2024-08-14 EP disclosed
US-12054568-B2 Optical material composition and optical material TOKUYAMA CORPORATION (JP) 2024-08-06 US disclosed
EP-3643735-B1 PHOTOCHROMIC POLYROTAXANE COMPOUND, AND CURABLE COMPOSITION CONTAINING SAID PHOTOCHROMIC POLYROTAXANE COMPOUND TOKUYAMA CORP (JP) 2024-07-31 EP disclosed
WO-2024048585-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION 株式会社クレハ 2024-03-07 WO disclosed
WO-2024048612-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT 株式会社クレハ 2024-03-07 WO disclosed
US-11767467-B2 Photochromic compound and curable composition containing said photochromic compound TOKUYAMA CORPORATION (JP) 2023-09-26 US disclosed
US-20040141230-A1 Optical materials having good ultraviolet absorbability and method for producing them KOSAKA MASAHISA (JP) 2004-07-22 US disclosed
EP-1422197-A1 DISPERSED INGREDIENT HAVING METAL−OXYGEN NIPPON SODA CO., LTD. (JP) 2004-05-26 EP disclosed
US-6673888-B2 PLASTIC LENSES HOYA CORPORATION (JP) 2004-01-06 US disclosed
US-20020132954-A1 Optical materials having good ultraviolet absorbability and method for producing them KOSAKA MASAHISA (JP) 2002-09-19 US disclosed
US-6448304-B1 POLYURETHANE, POLYTHIOURETHANE OR DIETHYLENE GLYCOL BISALLYLCARBONATE POLYMER; DIPPING IN SOLUTION CONTAINING A DIBENZOYLMETHANE OR A BENZOTRIZOLE COMPOUND; PLASTIC LENS FOR SPECTACLES WHICH ABSORBS ULTRAVIOLET RAYS; LOW YELLOWNESS HOYA CORPORATION (JP) 2002-09-10 US disclosed
US-6441119-B1 POLYMERIZING A PLASTIC LENS MONOMER SUCH AS A DIETHYLENE GLYCOL, BISALLYL CARBONATE MIXED WITH THE UV ABSORBENT 2-(2-HYDROXY-4-OCTYLOXYPHENYL)-BENZOTRIAZOLE; NONYELLOWING; EYEGLASSES HOYA CORPORATION (JP) 2002-08-27 US disclosed
EP-1085348-A2 Plastic lenses of good ultraviolet absorbability for spectacles and method for producing them HOYA CORPORATION (JP) 2001-03-21 EP disclosed
EP-1085349-A2 Plastic lenses having good ultraviolet absorbability, and method for the production thereof HOYA CORPORATION (JP) 2001-03-21 EP disclosed
US-5955206-A POLYTHIOETHERS AND ACRYLATE OR VINYL GROUPS FOR CURING TO FORM OPTICAL LENSES MITSUI CHEMICALS, INC. (JP) 1999-09-21 US disclosed
EP-0742244-A2 Durable polysulfide composition for optical material MITSUI TOATSU CHEMICALS, INC. (JP) 1996-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062548-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION CROCC, WASF2, DCXR LMNA 1472/4885CHRM2 3629/4885CHRM1 2836/4885
US-20260062512-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT EHMT1, EHMT2, ASH2L LMNA 2126/4885CHRM2 1152/4885CHRM1 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.